{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:07:53Z","timestamp":1788541673779,"version":"build-2803163510"},"reference-count":33,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Recent therapeutic advances, including bispecific antibodies (bsAbs), have improved outcomes for patients with relapsed\/refractory multiple myeloma (RRMM). However, early mortality (EM) remains a significant challenge, even in the era of novel immunotherapies. We conducted a multicenter, retrospective analysis of real-world patients with RRMM treated with commercial bsAbs to evaluate the incidence and causes of EM. Between May 2022 and June 2025, a total of 441 patients were treated across 7 countries. EM, defined as death within 12 months of therapy initiation, occurred in 148 patients (34%), with a median time from bsAb initiation to death of 2.87 months (interquartile range, 1.38-6.85). The leading cause of EM was progressive disease (72%), followed by infection (13%); regardless of the cause of death, 82% had active disease at the time of death. Our findings highlight that despite encouraging efficacy, EM remains high among real-world bsAb recipients, emphasizing the need for improved disease control strategies and supportive care interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019231","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T22:08:06Z","timestamp":1771970886000},"page":"2937-2946","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":false,"given":"Carlyn Rose","family":"Tan","sequence":"first","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[{"name":"2Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"de Meneze Silva Corraes","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[{"name":"4Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"4Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sireesha","family":"Asoori","sequence":"additional","affiliation":[{"name":"5University of San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrugakshi","family":"Dave","sequence":"additional","affiliation":[{"name":"6International Myeloma Foundation, Studio City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"7Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Morjaria","sequence":"additional","affiliation":[{"name":"7Department of Haematology, University College London Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-6267","authenticated-orcid":false,"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[{"name":"8Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-7873","authenticated-orcid":false,"given":"Jana","family":"Mihalyova","sequence":"additional","affiliation":[{"name":"8Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Hematopoietic Cell Transplant, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-4642","authenticated-orcid":false,"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[{"name":"10Department of Oncology, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"11Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"11Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"12Departamento de Hematolog\u00eda, Hospital 12 de Octubre, imas12, Complutense University, Centro Nacional de Investigaciones Oncologicas, mixtas de investigacion, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-2226","authenticated-orcid":false,"given":"Chandramouli","family":"Nagarajan","sequence":"additional","affiliation":[{"name":"13Department of Haematology, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-8919","authenticated-orcid":false,"given":"Susan","family":"Bal","sequence":"additional","affiliation":[{"name":"14Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[{"name":"14Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"15Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Steinbrunn","sequence":"additional","affiliation":[{"name":"15Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5340-1818","authenticated-orcid":false,"given":"Johannes M.","family":"Waldschmidt","sequence":"additional","affiliation":[{"name":"15Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Riedhammer","sequence":"additional","affiliation":[{"name":"15Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"16Division of Hematology-Oncology, Fred Hutch Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[{"name":"17Department of Hematology-Oncology, National University Cancer Institute, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3943-7229","authenticated-orcid":false,"given":"Allison","family":"Tso","sequence":"additional","affiliation":[{"name":"18Department of Haematology, Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"3Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-9813","authenticated-orcid":false,"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"5University of San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"additional","affiliation":[{"name":"10Department of Oncology, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"5","key":"2026050815173003400_bib1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"2026050815173003400_bib2","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/leu.2015.33","article-title":"Early mortality in multiple myeloma","volume":"29","author":"Costa","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2026050815173003400_bib3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ajh.24389","article-title":"Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients","volume":"91","author":"R\u00edos-Tamayo","year":"2016","journal-title":"Am J Hematol"},{"issue":"13","key":"2026050815173003400_bib4","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/cncr.34760","article-title":"A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma","volume":"129","author":"Grant","year":"2023","journal-title":"Cancer"},{"issue":"6","key":"2026050815173003400_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2026050815173003400_bib6","unstructured":"U.S. Food and Drug Administration\n          . FDA Approves Teclistamab-cqyv For Relapsed or Refractory Multiple Myeloma. U.S. Food and Drug Administration. Accessed 3 March 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma."},{"issue":"9","key":"2026050815173003400_bib7","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"2026050815173003400_bib8","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"24","key":"2026050815173003400_bib9","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"2026050815173003400_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/ejh.14353","article-title":"Talquetamab in multiple myeloma: efficacy, safety, and future directions","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur J Haematol"},{"issue":"22","key":"2026050815173003400_bib11","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/bloodadvances.2025016613","article-title":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1","volume":"9","author":"Schinke","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026050815173003400_bib12","doi-asserted-by":"crossref","first-page":"e70114","DOI":"10.1002\/hem3.70114","article-title":"A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"HemaSphere"},{"issue":"4","key":"2026050815173003400_bib13","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3324\/haematol.2024.286118","article-title":"Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program","volume":"110","author":"Perrot","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"2026050815173003400_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","article-title":"Elranatamab monotherapy in the real-world setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM","volume":"14","author":"Malard","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026050815173003400_bib15","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl_1","key":"2026050815173003400_bib16","first-page":"4760-4760","article-title":"Population-level trends in early mortality and overall survival of patients with multiple myeloma. Are we facing stagnation?","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2026050815173003400_bib17","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1016\/j.clml.2020.12.023","article-title":"Trends in early mortality from multiple myeloma: a population-based analysis","volume":"21","author":"Kumar","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2026050815173003400_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"issue":"4","key":"2026050815173003400_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jgo.2020.10.009","article-title":"Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: a population-based study","volume":"12","author":"Mian","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"2026050815173003400_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J"},{"issue":"13","key":"2026050815173003400_bib21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026050815173003400_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"2026050815173003400_bib23","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3324\/haematol.2024.286118","article-title":"Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program","volume":"110","author":"Perrot","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"2026050815173003400_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41408-025-01297-7","article-title":"Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium","volume":"15","author":"Pasvolsky","year":"2025","journal-title":"Blood Cancer J"},{"issue":"7","key":"2026050815173003400_bib27","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ymthe.2025.03.048","article-title":"Non-relapse mortality with bispecific antibodies: a systematic review and meta-analysis in lymphoma and multiple myeloma","volume":"33","author":"Tix","year":"2025","journal-title":"Mol Ther"},{"issue":"5","key":"2026050815173003400_bib28","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group Immunotherapy Committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026050815173003400_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026050815173003400_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026050815173003400_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026050815173003400_bib32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026050815173003400_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of intravenous immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"issue":"18","key":"2026050815173003400_bib34","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026050815173003400_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ajh.70108","article-title":"Predictors of delayed responses to teclistamab in multiple myeloma after initial non-response","volume":"101","author":"Banerjee","year":"2026","journal-title":"Am J Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2937\/2515744\/blooda_adv-2025-019231-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2937\/2515744\/blooda_adv-2025-019231-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:17:41Z","timestamp":1778267861000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/2937\/566834\/Early-mortality-with-bispecific-antibody-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019231","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,4,29]]}}}